SEHK:6160

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People’s Republic of China, the United States, and internationally.


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has BeiGene's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6160's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.5%

6160

5.9%

HK Biotechs

6.0%

HK Market


1 Year Return

44.9%

6160

25.2%

HK Biotechs

-4.0%

HK Market

Return vs Industry: 6160 exceeded the Hong Kong Biotechs industry which returned 25% over the past year.

Return vs Market: 6160 exceeded the Hong Kong Market which returned -4% over the past year.


Shareholder returns

6160IndustryMarket
7 Day7.5%5.9%6.0%
30 Day21.8%10.2%4.3%
90 Day13.4%17.0%-2.4%
1 Year44.9%44.9%25.3%25.2%-0.5%-4.0%
3 Yearn/a-0.7%-2.8%1.4%-9.2%
5 Yearn/a-7.2%-10.5%-9.3%-23.6%

Price Volatility Vs. Market

How volatile is BeiGene's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is BeiGene undervalued compared to its fair value and its price relative to the market?

4.74x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: 6160 (HK$104.3) is trading above our estimate of fair value (HK$74.95)

Significantly Below Fair Value: 6160 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 6160 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 6160 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6160's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6160 is overvalued based on its PB Ratio (4.7x) compared to the HK Biotechs industry average (2.9x).


Next Steps

Future Growth

How is BeiGene forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

48.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6160 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 6160 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 6160 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 6160's revenue (44.5% per year) is forecast to grow faster than the Hong Kong market (10.6% per year).

High Growth Revenue: 6160's revenue (44.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 6160 is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has BeiGene performed over the past 5 years?

-61.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6160 is currently unprofitable.

Growing Profit Margin: 6160 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6160 is unprofitable, and losses have increased over the past 5 years at a rate of -61.6% per year.

Accelerating Growth: Unable to compare 6160's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6160 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-30.2%).


Return on Equity

High ROE: 6160 has a negative Return on Equity (-40.59%), as it is currently unprofitable.


Next Steps

Financial Health

How is BeiGene's financial position?


Financial Position Analysis

Short Term Liabilities: 6160's short term assets ($3.6B) exceed its short term liabilities ($451.8M).

Long Term Liabilities: 6160's short term assets ($3.6B) exceed its long term liabilities ($788.4M).


Debt to Equity History and Analysis

Debt Level: 6160's debt to equity ratio (8.9%) is considered satisfactory.

Reducing Debt: 6160's debt to equity ratio has reduced from 50.1% to 8.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6160 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 6160 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is BeiGene's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6160's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6160's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6160's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6160's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6160's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.9yrs

Average management tenure


CEO

John Oyler (51yo)

10.42yrs

Tenure

US$12,575,474

Compensation

Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009.  ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD12.58M) is above average for companies of similar size in the Hong Kong market ($USD767.04K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
John Oyler
Co-Founder10.42yrsUS$12.58m6.24% $6.5b
Xiaobin Wu
GM of China & President2.08yrsUS$9.13m0.054% $55.9m
Xiaodong Wang
Co-Founder9.42yrsUS$4.00m0.73% $753.0m
Heng Liang
CFO & Chief Strategy Officer4.92yrsUS$4.19m0.00071% $734.5k
Jane Edna Huang
Chief Medical Officer of Hematology3.75yrsUS$3.61m0.019% $20.0m
Daniel Maller
Vice President of Finance & Accountingno datano datano data
Lucy Li
Investor Contactno datano datano data
Scott Samuels
Senior VP & General Counselno datano datano data
Diana Lee Francis
VP and Global Head of Quality & Regulatory Compliance3yrsno datano data
Luo Lusong
Head of Discovery Biology & Senior VP9.67yrsno datano data

4.9yrs

Average Tenure

56yo

Average Age

Experienced Management: 6160's management team is considered experienced (4.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
John Oyler
Co-Founder10.42yrsUS$12.58m6.24% $6.5b
Xiaodong Wang
Co-Founder9.42yrsUS$4.00m0.73% $753.0m
Thomas Malley
Independent Non-Executive Director & Member of the Scientific Advisory Committee0.33yrUS$372.47k0.040% $40.9m
Michael Goller
Independent Non-Executive Director & Member of the Scientific Advisory Committee0.33yrUS$354.97k0.00092% $951.7k
Donald Glazer
Independent Non-Executive Director7.33yrsUS$362.47k0.35% $358.6m
Anthony Hooper
Non Executive Director & Chairman of the Commercial Advisory Committee0.33yrno datano data
Jing-Shyh Su
Independent Non-Executive Director & Member of the Commercial Advisory Committee2.17yrsUS$356.64kno data
Yung-cheng Chen
Independent Non-Executive Director & Member of the Commercial Advisory Committee0.33yrUS$367.47kno data
Ranjeev Krishana
Independent Lead Director & Member of the Commercial Advisory Committee0.33yrUS$357.47k0.00092% $951.7k
Qingqing Yi
Independent Non-Executive Director & Member of the Scientific Advisory Committee5.67yrsUS$370.80kno data

0.3yrs

Average Tenure

53.5yo

Average Age

Experienced Board: 6160's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.8%.


Top Shareholders

Company Information

BeiGene, Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BeiGene, Ltd.
  • Ticker: 6160
  • Exchange: SEHK
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$13.348b
  • Listing Market Cap: US$103.446b
  • Shares outstanding: 77.59m
  • Website: https://www.beigene.com

Number of Employees


Location

  • BeiGene, Ltd.
  • No.30 Science Park Road
  • Zhong-Guan-Cun Life Science Park
  • Beijing
  • 102206
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BGNENasdaqGS (Nasdaq Global Select)YesSPONSORED ADRUSUSDFeb 2016
49BADB (Deutsche Boerse AG)YesSPONSORED ADRDEEURFeb 2016
BGNE NBMV (Bolsa Mexicana de Valores)YesSPONSORED ADRMXMXNFeb 2016
49BDB (Deutsche Boerse AG)Ordinary SharesDEEURAug 2018
6160SEHK (The Stock Exchange of Hong Kong Ltd.)Ordinary SharesHKHKDAug 2018

Biography

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People’s Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin’s lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company’s clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; and Hutchison China MediTech Limited. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People’s Republic of China. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/06 14:09
End of Day Share Price2020/06/05 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.